<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936857</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA037441_VNE</org_study_id>
    <nct_id>NCT01936857</nct_id>
  </id_info>
  <brief_title>Buprenorphine to Improve HIV Care Engagement and Outcomes</brief_title>
  <official_title>Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanoi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Vietnam: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two models of substance abuse treatment in Vietnam,
      and how they each affect HIV care. In Vietnam, the current model for treating people with
      HIV who are also dependent on opioids is to refer them to methadone maintenance treatment
      centers. The new model the protocol will study is treatment of HIV and opioid dependence
      with buprenorphine/naloxone and counseling in the HIV clinic.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HIV Viral Suppression</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>HIV-1 RNA &lt; 200 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Receipt of Antiretroviral Therapy (ART)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Initiation of and retention on treatment with antiretroviral medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in HIV care</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Attendance at scheduled HIV clinic visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heroin use</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>HIV</condition>
  <condition>Substance Related Disorders</condition>
  <arm_group>
    <arm_group_label>Buprenorphine/naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Office based treatment of opioid dependence with buprenorphine/naloxone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone Maintenance Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Referral to methadone maintenance therapy for treatment of opioid dependence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>Buprenorphine/naloxone induction begins with a 2mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Subjects will return at least twice in the first week for re-evaluation and take-outs, then weekly for 4 weeks, then every 2 weeks for 4 weeks, then monthly, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg and maximum take-out period of 4 weeks, as deemed clinically appropriate by the study physician.</description>
    <arm_group_label>Buprenorphine/naloxone</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone Maintenance Therapy</intervention_name>
    <description>Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.</description>
    <arm_group_label>Methadone Maintenance Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New to HIV care or registered but not on ART

          -  No ART in past 3 months

          -  Current DSM-IV opioid dependence

          -  Interested in receiving treatment

          -  Age 18-65

          -  CD4 &lt; 350 cells/mL

          -  Willing to practice an effective method of birth control, if female

        Exclusion Criteria:

          -  Known hypersensitivity to buprenorphine or naloxone

          -  AST &amp; ALT &gt; 5x upper limit

          -  Pregnancy

          -  Serious medical or psychiatric illness in past 30 days (e.g. opportunistic infection,
             psychosis) that precludes safe participation in the opinion of study physician

          -  Methadone maintenance treatment within 30 days of consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philip T Korthuis, MD, MPH</last_name>
    <phone>503-494-8044</phone>
    <email>korthuis@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giang M Le, MD</last_name>
    <phone>84-0913281842</phone>
    <email>leminhgiang@hmu.edu.vn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Viet Tiep HIV Clinic</name>
      <address>
        <city>Hai Phong</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoang Mai HIV Clinic</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dong Da HIV Clinic</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ha Dong HIV Clinic</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Outpatient HIV Clinic of 09 Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>P. Todd Korthuis</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
